For example, the androgen (AR) and estrogen (both ESR1 and ESR2) nuclear hormone receptors are known to be relevant in prostate and breast cancers, and the alpha-type platelet-derived (PDGFRA) and epidermal (EGFR) growth factor receptors are recognised angiogenesis factors. This evidence concerns the gene AR and breast carcinoma.